That this is the first time a compulsory licence has been granted in India is in itself important. INDIA'S long struggle to ensure access to affordable medicines for its people recently took a positive and interesting turn. In early March, just before he demitted office, Controller General of Patents P.H. Kurian passed an order on an application filed by Natco Pharma, headquartered in Hyderabad, requesting a licence to produce an anti-cancer...
More »SEARCH RESULT
RTE Act can be a model for the world: Kapil Sibal
-The Times of India The RTE Act is an opportunity to break gender, caste, class and community barriers that threaten to damage the social fabric of our democracy and create fissures that could be ruinous to the country, writes Union HRD minister Kapil Sibal. The Supreme Court judgment upholding the constitutional validity of the Right of Children to Free and Compulsory Education (RTE) Act has once again focused public attention on education....
More »Drug and duplicity-Brook K Baker
NOVARTIS has long been suing the Government of India to eliminate or weaken Section 3(d) of the Patents (Amendment) Act, 2005, which established strict standards of patentability in order to prevent the ever-greening of patent monopolies on medicines. Although Novartis lost in 2007 its initial efforts to have Section 3(d) declared unconstitutional and violative of international norms for national patent regimes, it has persisted in appealing and re-appealing the denial...
More »CIC to CJI: Lend your voice to strengthen, not curb, RTI
-The Hindu Expressing concern over the reported comments of the Chief Justice of India S.H. Kapadia that Right to Information queries were impeding the working of Judges, the Chief Information Commissioner Shailesh Gandhi had written to the CJI to lend his powerful voice to increasing the effectiveness and reach of RTI and not support those who seek to curb it. In a recent letter addressed to Mr. Justice Kapadia, the CIC drew...
More »Patent to plunder -Amit Sengupta
India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...
More »